Ventavis
Treatment for Pulmonary HypertensionCoTherix, Inc. Announces Filing of Ventavis NDA
Click here for more information on Ventavis
SOUTH SAN FRANCISCO, Calif., July 01, 2004 -- CoTherix, Inc. announced today that the Company submitted yesterday its new drug application (NDA) to the United States Food and Drug Administration seeking approval to market Ventavis (iloprost solution for inhalation) as a therapy for the treatment of pulmonary arterial hypertension.
Ventavis is currently marketed in various European countries by Schering AG, Germany. CoTherix licensed the exclusive U.S. rights to Ventavis from Schering AG in October 2003.
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. CoTherix's lead product candidate, Ventavis, is an inhaled formulation of iloprost, a prostacyclin analog. The Company is developing Ventavis for the treatment of pulmonary arterial hypertension, a highly debilitating disease characterized by severe constriction of the blood vessels of the lungs.
For more information, please visit www.cotherix.com.
Posted: July 2004
Related Articles
- Ventavis CoTherix, Inc. - Treatment for Pulmonary Arterial Hypertension - December 29, 2004
- CoTherix, Inc. Announces Priority Review Designation by the FDA for Ventavis NDA - September 8, 2004
